EC approves Pfizer’s Talzenna combo for prostate cancer treatment

09 Jan 2024
www.pharmaceutical-technology.com
Phase 3Drug ApprovalClinical ResultGene Therapy
EC approves Pfizer’s Talzenna combo for prostate cancer treatment
Preview
Source: Pharmaceutical Technology
The EC approval extends use of Pfizer’s Talzenna combo to all 27 member states in the EU plus Liechtenstein, Iceland and Norway. Credit: YES Market Media / Shutterstock.com.
The European Commission (EC) has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults with metastatic castration-resistant prostate cancer (mCRPC) where chemotherapy is not indicated clinically.
An oral inhibitor of poly ADP-ribose polymerase (PARP), Talzenna is indicated to be used along with Xtandi (enzalutamide).
Talzenna becomes the first and only PARP inhibitor licensed in the European Union (EU) for use with Xtandi in mCRPC patients irrespective of gene mutation status.
The EC approval includes all 27 EU member states along with Liechtenstein, Iceland and Norway.
The development is based on findings from the two-part, randomised, two-cohort, multicentre, placebo-controlled double-blind Phase III TALAPRO-2 clinical trial of Talzenna plus Xtandi.
It enrolled 1,106 patients across the US, Canada, Europe, South America and Asia-Pacific.
According to data from Cohort 1 of the trial, Talzenna plus Xtandi demonstrated a reduction of disease progression or mortality risk of 37% compared with placebo plus Xtandi.
The trial also met the primary endpoint of improvement in radiographic progression-free survival.
The safety profile of the combination treatment was in line with those of the individual medicines previously reported.
In June 2023, the combination regimen received approval from the US Food and Drug Administration to treat HRR gene-mutated mCRPC in adults.
Pfizer executive vice-president and chief oncology officer Chris Boshoff stated: “The approval of Talzenna in combination with Xtandi represents an important advancement for men living with prostate cancer in Europe.
“The results from the pivotal TALAPRO-2 trial showed that this combination offers an effective treatment that addresses disease progression in patients with or without any specific gene mutation.”
The latest development comes after Pfizer Canada received approval from Health Canada for its adeno-associated viral (AAV) vector-based gene therapy Beqvez (fidanacogene elaparvovec) to treat haemophilia B.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.